From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic

about receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. Our lead asset, RPC1063, is being developed as an oral therapy for relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Receptos is currently enrolling a Phase 3 study in RMS called RADIANCE, and has completed enrollment in a Phase 2 study in ulcerative colitis (a form of IBD) called TOUCHSTONE. Receptos is conducting a Phase 2 trial for RPC4046, a monoclonal antibody directed against interleukin-13 (IL-13), in patients with eosinophilic esophagitis (EoE).

news

November 18, 2014
Receptos Announces Pricing of Underwritten Public Offering of Common Stock… MORE »

November 17, 2014
Receptos Announces Proposed Underwritten Public Offering of Common Stock… MORE »

November 6, 2014
Receptos to Present at Credit Suisse Healthcare Conference… MORE »

November 4, 2014
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results… MORE »